Gene: ASCL1

429
ASH1|HASH1|MASH1|bHLHa46
achaete-scute family bHLH transcription factor 1
protein-coding
12q23.2
Ensembl:ENSG00000139352 MIM:100790 Vega:OTTHUMG00000169967 UniprotKB:P50553
NG_008950.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.646e-1 (AD)  7.246e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SOX210.836
KCNJ100.782
GATM0.777
BMP70.774
EMID10.763
PIPOX0.754
MYO100.751
PHGDH0.739
GPR37L10.737
PYGM0.734

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLIT3-0.445
TMEM159-0.44
OCA2-0.438
TPH2-0.435
HRH2-0.434
CLVS1-0.431
IL12RB2-0.423
WNT1-0.419
ANKRD63-0.418
HTR4-0.418

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5171131,1-bis(4-hydroxyphenyl)cyclohexane"1,1-bis(4-hydroxyphenyl)cyclohexane results in increased expression of ASCL1 mRNA"28591870
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of ASCL1 mRNA"27291303
C0235142,6-dinitrotoluene"2,6-dinitrotoluene affects the expression of ASCL1 mRNA"21346803
C5495433-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid results in decreased expression of ASCL1 mRNA25716159
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of ASCL1 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C016601afimoxifeneafimoxifene results in decreased expression of ASCL1 mRNA19901195
D000643Ammonium ChlorideAmmonium Chloride affects the expression of ASCL1 mRNA16483693
D001151ArsenicArsenic results in decreased expression of ASCL1 mRNA24019935
D001280AtrazineAtrazine results in decreased expression of ASCL1 mRNA25929836
D001280AtrazineAtrazine results in decreased expression of ASCL1 mRNA22378314
D004958Estradiol[Estradiol binds to ESR2 protein] which results in increased expression of ASCL1 mRNA20404318
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ASCL1 mRNA19619570
D004958EstradiolEstradiol results in increased expression of ASCL1 mRNA19619570
D004958EstradiolEstradiol results in increased expression of ASCL1 mRNA20068009
C044887beta-methylcholinebeta-methylcholine affects the expression of ASCL1 mRNA21179406
C095105bexarotene[bexarotene co-treated with Tamoxifen] results in decreased expression of ASCL1 mRNA17630414
C006780bisphenol Abisphenol A affects the methylation of ASCL1 promoter27334623
C006780bisphenol Abisphenol A results in increased expression of ASCL1 mRNA26063408
C006780bisphenol Abisphenol A results in decreased expression of ASCL1 mRNA25181051
C000541cyclopaminecyclopamine results in decreased expression of ASCL1 mRNA21703336
C010902decabromobiphenyl etherdecabromobiphenyl ether results in increased expression of ASCL1 mRNA23914054
D0151279,10-Dimethyl-1,2-benzanthracene"9,10-Dimethyl-1,2-benzanthracene results in increased expression of ASCL1 mRNA"22485181
D004610Ellagic AcidEllagic Acid results in increased expression of ASCL1 mRNA12002526
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of ASCL1 mRNA23550701
D005395Fish OilsFish Oils results in decreased expression of ASCL1 mRNA22464816
C475919hydroxytamoxifenhydroxytamoxifen results in increased expression of ASCL1 mRNA16849584
C561695(+)-JQ1 compound(+)-JQ1 compound inhibits the reaction [BRD4 protein binds to ASCL1 enhancer]26253517
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of ASCL126253517
D007649KetamineKetamine results in decreased expression of ASCL1 mRNA20080153
D008344Maneb[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA23017109
D008748Methylcholanthrene"[Methylcholanthrene co-treated with Nanotubes, Carbon] results in increased expression of ASCL1 mRNA"25926378
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of ASCL1 mRNA28001369
C523799MRK 003MRK 003 results in increased expression of ASCL1 mRNA17804716|1977528
D037742Nanotubes, Carbon"[Methylcholanthrene co-treated with Nanotubes, Carbon] results in increased expression of ASCL1 mRNA"25926378
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of ASCL1 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of ASCL1 mRNA"25554681
C031721naphthaleneASCL1 protein inhibits the reaction [naphthalene results in decreased expression of CYP2F2 mRNA]20554700
C031721naphthaleneASCL1 protein inhibits the reaction [naphthalene results in decreased expression of SCGB1A1 protein]20554700
C031721naphthaleneASCL1 protein inhibits the reaction [naphthalene results in increased expression of SYP protein]20554700
C031721naphthalenenaphthalene results in increased expression of ASCL1 protein20554700
C007350nitrofennitrofen results in decreased expression of ASCL1 mRNA17618886
C025589ochratoxin Aochratoxin A results in decreased expression of ASCL1 mRNA21703336
C025589ochratoxin ASHH protein modified form inhibits the reaction [ochratoxin A results in decreased expression of ASCL1 mRNA]21703336
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
D010269Paraquat[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA23017109
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of ASCL1 mRNA26272509
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ASCL1 mRNA19710929
D020959PolyethylenePolyethylene results in decreased expression of ASCL1 mRNA23203475
D011441PropylthiouracilPropylthiouracil results in increased expression of ASCL1 mRNA24780913
C059514resveratrolresveratrol results in decreased expression of ASCL1 mRNA21184191
C059514resveratrolresveratrol results in decreased expression of ASCL1 protein21184191
C059514resveratrolresveratrol results in increased expression of ASCL1 mRNA12002526
D012524SarinSarin results in decreased expression of ASCL1 mRNA19522546
D012524SarinSarin results in increased expression of ASCL1 mRNA19522546
D012834SilverSilver results in decreased expression of ASCL1 mRNA26551752
C017947sodium arsenitesodium arsenite results in decreased expression of ASCL1 mRNA25448440|2715859
D018038Sodium SeleniteSodium Selenite results in decreased expression of ASCL1 mRNA18175754
D012999SomanSoman results in increased expression of ASCL1 mRNA19281266
D053260SootSoot results in decreased expression of ASCL1 mRNA26551751
D013629Tamoxifen[bexarotene co-treated with Tamoxifen] results in decreased expression of ASCL1 mRNA17630414
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in decreased expression of ASCL1 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ASCL1 mRNA19619570|1990119
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ASCL1 mRNA21570461|2405805
D019284ThapsigarginThapsigargin results in increased expression of ASCL1 mRNA22378314
C009495titanium dioxidetitanium dioxide results in decreased expression of ASCL1 mRNA23557971
D014212TretinoinTretinoin results in decreased expression of ASCL1 mRNA23724009
D014212TretinoinTretinoin results in increased expression of ASCL1 mRNA21934132
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of ASCL1 mRNA24935251|2627250
C012589trichostatin Atrichostatin A results in decreased expression of ASCL1 mRNA15901671
D014501UraniumUranium results in increased expression of ASCL1 mRNA27639536
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of ASCL1 mRNA23179753|2519280
D014635Valproic AcidValproic Acid results in increased expression of ASCL1 mRNA23179753|2627250
D014635Valproic AcidValproic Acid results in decreased expression of ASCL1 mRNA15901671
D000069470Venlafaxine HydrochlorideVenlafaxine Hydrochloride results in decreased expression of ASCL1 mRNA25423262
D000069470Venlafaxine HydrochlorideVenlafaxine Hydrochloride results in increased expression of ASCL1 mRNA25423262
C025643vinclozolinvinclozolin results in increased expression of ASCL1 mRNA23869203
D014801Vitamin AVitamin A deficiency results in increased expression of ASCL1 mRNA12555267
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ASCL1 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of ASCL1 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000977RNA polymerase II regulatory region sequence-specific DNA binding-IBA21873635  
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IDA11736660  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0000989transcription factor activity, transcription factor binding-ISS-  
GO:0001078transcriptional repressor activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IDA11736660  
GO:0003677DNA binding-ISS-  
GO:0003682chromatin binding-IEA-  
GO:0003700DNA-binding transcription factor activityCONTRIBUTES_TOIBA21873635  
GO:0003700DNA-binding transcription factor activity-IDA10903890  
GO:0005515protein binding-IPI10903890  
GO:0042803protein homodimerization activity-IEA-  
GO:0043425bHLH transcription factor binding-IPI10903890  11940670  
GO:0070888E-box binding-IDA10903890  11736660  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IDA11736660  
GO:0001764neuron migration-IEA-  
GO:0003358noradrenergic neuron development-ISS-  
GO:0003359noradrenergic neuron fate commitment-IMP14532329  
GO:0006351transcription, DNA-templated-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-IBA21873635  
GO:0007219Notch signaling pathway-IDA16160079  
GO:0007346regulation of mitotic cell cycle-IEA-  
GO:0007400neuroblast fate determination-IEA-  
GO:0007405neuroblast proliferation-IEA-  
GO:0010226response to lithium ion-IEA-  
GO:0010468regulation of gene expression-ISS-  
GO:0014003oligodendrocyte development-IEA-  
GO:0021527spinal cord association neuron differentiation-IEA-  
GO:0021530spinal cord oligodendrocyte cell fate specification-IEA-  
GO:0021750vestibular nucleus development-IEA-  
GO:0021892cerebral cortex GABAergic interneuron differentiation-IEP12050665  
GO:0021902commitment of neuronal cell to specific neuron type in forebrain-IEA-  
GO:0021954central nervous system neuron development-IEA-  
GO:0021987cerebral cortex development-IEA-  
GO:0022008neurogenesis-IDA19008346  
GO:0030182neuron differentiation-ISS-  
GO:0030856regulation of epithelial cell differentiation-IEA-  
GO:0032526response to retinoic acid-IEP12000752  
GO:0043066negative regulation of apoptotic process-IMP17507989  
GO:0043525positive regulation of neuron apoptotic process-IEA-  
GO:0045665negative regulation of neuron differentiation-IDA12000752  
GO:0045666positive regulation of neuron differentiation-ISS-  
GO:0045747positive regulation of Notch signaling pathway-IEA-  
GO:0045787positive regulation of cell cycle-IEA-  
GO:0045892negative regulation of transcription, DNA-templated-IDA11736660  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA10903890  
GO:0048469cell maturation-IEA-  
GO:0048485sympathetic nervous system development-NAS10903890  
GO:0048663neuron fate commitment-ISS-  
GO:0048665neuron fate specification-ISS-  
GO:0048666neuron development-ISS-  
GO:0050767regulation of neurogenesis-IBA21873635  
GO:0050883musculoskeletal movement, spinal reflex action-IEA-  
GO:0051593response to folic acid-IEA-  
GO:0060163subpallium neuron fate commitment-IEA-  
GO:0060165regulation of timing of subpallium neuron differentiation-IEA-  
GO:0060166olfactory pit development-IEA-  
GO:0060487lung epithelial cell differentiation-NAS12858003  
GO:0060579ventral spinal cord interneuron fate commitment-ISS-  
GO:0061100lung neuroendocrine cell differentiation-IEA-  
GO:0061102stomach neuroendocrine cell differentiation-IEA-  
GO:0061103carotid body glomus cell differentiation-IEA-  
GO:0061104adrenal chromaffin cell differentiation-IEA-  
GO:0061549sympathetic ganglion development-ISS-  
GO:0070849response to epidermal growth factor-IEA-  
GO:0071259cellular response to magnetism-IEA-  
GO:2000179positive regulation of neural precursor cell proliferation-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IDA12858003  17507989  18311112  
GO:0043025neuronal cell body-IEA-  
GO:0090575RNA polymerase II transcription factor complex-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
20124469ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus. (2010 Feb)Improgo MRMol Cancer Res
24037524ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation. (2014 Jul 17)Kosari FOncogene